Nautilus Biotechnolgy (NAUT) Gets a Hold Rating from Morgan Stanley

In a report released today, Tejas Savant from Morgan Stanley maintained a Hold rating on Nautilus Biotechnolgy (NAUTResearch Report), with a price target of $6.00. The company’s shares closed last Wednesday at $2.89, close to its 52-week low of $2.53.

According to, Savant is a 1-star analyst with an average return of -5.1% and a 42.7% success rate. Savant covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Adaptive Biotechnologies, and Pacific Biosciences.

Nautilus Biotechnolgy has an analyst consensus of Moderate Buy, with a price target consensus of $6.33, implying an 119.8% upside from current levels. In a report released today, Goldman Sachs also maintained a Hold rating on the stock with a $2.00 price target.

See the top stocks recommended by analysts >>

Nautilus Biotechnolgy’s market cap is currently $351M and has a P/E ratio of -5.69.

Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NAUT in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ARYA Sciences Acquisition Corp III is a blank check company.

Read More on NAUT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More